Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patients

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON24467

Source Nationaal Trial Register

Brief title CIRCUS Study

Health condition

metastatic prostate cancer

Sponsors and support

Primary sponsor: Erasmus Medical Center Source(s) of monetary or material Support: Erasmus Medical Center

Intervention

Outcome measures

Primary outcome

The rate of mPC patients with quantifiable ctDNA taken pre-treatment.

Secondary outcome

1 - Quantification of Circulating tumor DNA to assess treatment response in metastat ... 17-06-2025

- The percentage of blood samples with sufficient ctDNA.
- The interval between detected ctDNA and PSA response during treatment.
- The correlation between ctDNA response and progression-free survival.

Study description

Study objective

With the quantification of circulating tumor DNA treatment response assessment will improve in metastatic prostate cancer patients.

Study design

Enrolment should be completed within 3 years.

Intervention

Repeated blood drawns and urine collection

Contacts

Public

afdeling Interne Oncologie - Erasmus MC Kanker Instituut, kamer Be-414a

L.F. van Dessel Postbus 2040

Rotterdam 3000 CA The Netherlands Tel.: 010-7044375 **Scientific** afdeling Interne Oncologie - Erasmus MC Kanker Instituut, kamer Be-414a

L.F. van Dessel Postbus 2040

Rotterdam 3000 CA The Netherlands Tel.: 010-7044375

2 - Quantification of Circulating tumor DNA to assess treatment response in metastat ... 17-06-2025

Eligibility criteria

Inclusion criteria

- Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Measurable metastatic lesion(s) according to PCWG2 and/or RECIST 1.1 criteria
- Intention to start (new) line of systemic treatment
- Written informed consent

- Willingness and capacity to follow the protocol specified visits for blood sampling for the total duration of the study.

- Age \geq 18 years.
- WHO performance status \leq 2.
- Concurrent participation in CPCT-02 study

Exclusion criteria

NA

Study design

Design

Study type:	
Intervention model:	
Masking:	
Control:	

Observational non invasive Other Open (masking not used) N/A , unknown

Recruitment

NL Recruitment status:

Recruiting

3 - Quantification of Circulating tumor DNA to assess treatment response in metastat ... 17-06-2025

Start date (anticipated):	08-04-2016
Enrollment:	95
Туре:	Anticipated

Ethics review

Positive opinion	
Date:	31-03-2016
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL5625
NTR-old	NTR5732
Other	: MEC-2016-081

Study results